ライフサイエンスコーパス: lamivudine

1 zidovudine plus lamivudine, or abacavir plus lamivudine).

2 ibitors (tenofovir/emtricitabine or abacavir/lamivudine).

3 selected tenofovir-emtricitabine or abacavir-lamivudine.

4 All of them were successfully treated with Lamivudine.

5 olerability than dolutegravir, abacavir, and lamivudine.

6 Each reactivation was treated with Lamivudine.

7 r alafenamide to dolutegravir, abacavir, and lamivudine.

8 nz, with tenofovir/emtricitabine or abacavir/lamivudine.

9 e antiviral prophylaxis strategy is lifelong lamivudine.

10 fficient for establishing resistance against lamivudine.

11 84V mutant in the presence of etravirine and lamivudine.

12 or continued oral cabotegravir plus abacavir-lamivudine.

13 relative to oral cabotegravir plus abacavir-lamivudine.

14 stopping therapy than has been reported with lamivudine.

15 ence was determined prior to availability of lamivudine.

16 sus coformulated dolutegravir, abacavir, and lamivudine.

17 cardiovascular event, all of which involved lamivudine.

18 + G), and all had previously been exposed to lamivudine.

19 first-line antiviral agents are superior to lamivudine.

20 n in those given dolutegravir, abacavir, and lamivudine (10% [n=32] vs 23% [n=72]; p<0.0001).

21 randomized to entecavir 0.5 mg (n = 354) or lamivudine 100 mg (n = 355) once daily.

22 f lopinavir 400 mg and ritonavir 100 mg plus lamivudine 150 mg, both twice daily.

23 r (2 RCTs; 600 patients) and HBeAg loss with lamivudine (2 RCTs; 318 patients).

24 deoxy-5-fluoro-3'-thiacytidine, (-)-FTC] and lamivudine, [(-)-2,3'-dideoxy-3'-thiacytidine, (-)-3TC]

25 namide than with dolutegravir, abacavir, and lamivudine (26% [n=82] vs 40% [n=127]), the difference b

26 s given with efavirenz 600 mg once a day and lamivudine 300 mg once a day.

27 ted dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg, with matching placebo, once daily for

28 y group, n = 69) or combined with zidovudine/lamivudine 300/150 mg twice daily (triple therapy group,

29 ned to receive efavirenz, both with abacavir-lamivudine; 322 (70%) and 324 (70%), respectively, compl

30 hanges; all levels increased with zidovudine/lamivudine (3TC) and abacavir/3TC (except triglycerides,

31 ypersusceptibility to the nucleoside analogs lamivudine (3TC) and tenofovir at both the virus and enz

32 andomized trial compared abacavir (ABC) plus lamivudine (3TC) and ZDV+3TC as part of a dual or triple

33 omes of children given zidovudine (ZDV) plus lamivudine (3TC) as a 2-drug PEP regimen.

34 ity induce the appearance of proviruses with lamivudine (3TC) drug resistance-associated mutations be

35 nd HIV-2, all treated with zidovudine (ZDV), lamivudine (3TC), and lopinavir-ritonavir (LPV/r), were

36 AZT), stavudine (d4T), didanosine (ddI), and lamivudine (3TC), and the nucleotide RTI inhibitor tenof

37 Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricit

38 mized to receive sdNVP and either zidovudine/lamivudine (3TC), tenofovir/emtricitabine (FTC), or lopi

39 e 5 most common NRTI pairs: zidovudine (ZDV)/lamivudine (3TC), ZDV/didanosine (ddI), stavudine (d4T)/

40 of dual therapy with dolutegravir (DTG) and lamivudine (3TC).

41 cy of 1 or more TDF-containing regimens: TDF/lamivudine (3TC)/nevirapine (NVP) (n = 3), TDF/ emtricit

42 ting of tenofovir (TDF), abacavir (ABC), and lamivudine (3TC); (2) lower fold resistance associated w

43 or the triphosphate forms of antiviral drugs lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP) pro

44 iphosphate (L-dCTP), or the triphosphates of lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP) wit

45 sphates of chain-terminating antiviral drugs lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP), we

46 9%; 95% CI, 90.2%-97.7%) and lowest for ZDV+ lamivudine [3TC]+LPV/r (59.1%; 95% CI, 36.2%-82.0%).

47 atives of (-)-2',3'-dideoxy-3'-thiacytidine (lamivudine, 3TC, 1) were synthesized and evaluated for t

48 ed with AZT (Zidovudine 100 mg/kg/day), 3TC (Lamivudine 50 mg/kg/day) or D4T (Stavudine 10 mg/kg/day)

49 ceived oral cabotegravir 30 mg plus abacavir-lamivudine 600-300 mg once daily.

50 Subjects received DTG (50 mg) plus abacavir/lamivudine (600/300 mg) once daily.

51 ily treatment with DTG (50 mg) plus abacavir-lamivudine (600/300 mg).

52 Five HAART drugs (ritonavir, indinavir, lamivudine, abacavir, and AZT) significantly decreased e

53 Five other HAART drugs (indinavir, lamivudine, abacavir, AZT, and ddI) and the 3-plex signi

54 Lamivudine, abacavir, zidovudine, emtricitabine, and ten

55 transcriptase inhibitor (NRTI) backbone with lamivudine/abacavir (3TC/ABC) as a commonly used alterna

56 (n=64) were randomized to receive zidovudine/lamivudine/abacavir (triple-nucleoside regimen), zidovud

57 plus EFV (3-drug EFV regimen) or zidovudine/lamivudine/abacavir plus EFV (4-drug EFV regimen).

58 en-label ATV/r or EFV combined with abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC

59 Trials Group A5202 compared blinded abacavir/lamivudine (ABC/3TC) to tenofovir DF/emtricitabine (TDF/

60 ficiency virus-infected subjects to abacavir-lamivudine (ABC/3TC) versus tenofovir DF-emtricitabine (

61 enofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC).

62 ing of HIV antivirals (stavudine, tenofovir, lamivudine, acyclovir, and zidovudine) was analyzed with

63 s with a low barrier to resistance are used (lamivudine, adefovir).

64 ation with tenofovir disoproxil fumarate and lamivudine after initiation of RIF (10 mg/kg/day).

65 blished pilot study of 1-year treatment with lamivudine/alpha interferon (IFN-alpha) were investigate

66 leoside reverse transcriptase (RT) inhibitor lamivudine (also known as 3TC) is associated with a subs

67 also increased cross-resistance with TAMs to lamivudine and abacavir, but not stavudine or didanosine

68 , and telbivudine offer greater potency than lamivudine and adefovir dipivoxil.

69 survey highlights the impact of exposure to lamivudine and adefovir on development of drug resistanc

70 De-novo combination of lamivudine and adefovir reduces the rate of antiviral re

71 stance mutation N236T (in 1 sample), and the lamivudine and adefovir-resistance mutations V173L, L180

72 was to evaluate the virological responses to lamivudine and emtricitabine in recommended cART.

73 of E138K together with M184I, which confers lamivudine and emtricitabine resistance in most patients

74 ency virus type 1 (HIV-1) infection consider lamivudine and emtricitabine to be interchangeable compo

75 The virological responses to lamivudine and emtricitabine were compared by multivaria

76 stablished although L-deoxycytidine analogs (lamivudine and emtricitabine) and L-thymidine (telbivudi

77 Although lamivudine and emtricitabine, two L-deoxycytidine analog

78 DP, or the diphosphates and triphosphates of lamivudine and emtricitabine.

79 relevant for settings with extensive use of lamivudine and for settings where generic lamivudine wil

80 The antiretrovirals were zidovudine/lamivudine and nelfinavir or lopinavir/ritonavir.

81 xed-dose-combination paediatric tablets with lamivudine and nevirapine or efavirenz.

82 isoproxil fumarate (TDF), emtricitabine, and lamivudine and potential transmission of resistance to t

83 e incidence of birth defects associated with lamivudine and tenofovir use during pregnancy is not inc

84 Exposure to lamivudine and to lamivudine-stavudine were also associa

85 A 1-week "tail" of lamivudine and zidovudine after SD-NVP decreases the ris

86 sufficient for high-level resistance to both lamivudine and zidovudine in HIV-2, and the combination

87 l drugs (abacavir, acyclovir, emtricitabine, lamivudine and zidovudine) via both bio- and phototransf

88 tratified by prior and/or concomitant use of lamivudine and/or emtricitabine.

89 nation antiretroviral therapy that contained lamivudine and/or tenofovir.

90 The long-term studies of lamivudine (and adefovir) show a consistent reduction in

91 l fumarate and emtricitabine or abacavir and lamivudine) and with no resistance were randomized to co

92 ing sensitivity to emtricitabine, tenofovir, lamivudine, and abacavir; and an estimated glomerular fi

93 initiation of HIV treatment with zidovudine, lamivudine, and either nevirapine or ritonavir-boosted l

94 iral therapy (DAART) for HIV/HBV (tenofovir, lamivudine, and emtricitabine) in a large cohort encompa

95 drugs (efavirenz, tenofovir, emtricitabine, lamivudine, and indinavir), only efavirenz increased ER

96 mtricitabine (zidovudine alone); zidovudine, lamivudine, and lopinavir-ritonavir (zidovudine-based AR

97 ed to receive either triple ARV (zidovudine, lamivudine, and lopinavir/ritonavir during pregnancy and

98 ents on the first-line regimen of stavudine, lamivudine, and nevirapine the benefits of viral load or

99 recommended first-line regimen of stavudine, lamivudine, and nevirapine to second-line antiretroviral

100 ; ARR, 1.31; 95% CI, 1.13-1.52); zidovudine, lamivudine, and NPV (ZDV-3TC-NVP) (647 of 1365 [47.4%];

101 d vaccination alone; the use of telbivudine, lamivudine, and tenofovir appears to be safe in pregnanc

102 pill alternative (generic efavirenz, generic lamivudine, and tenofovir) will decrease cost but may re

103 Current exposure to abacavir, efavirenz, lamivudine, and zidovudine was significantly associated

104 One of these-efavirenz, lamivudine, and zidovudine-was the second most commonly

105 on, compound 24 also showed activity against lamivudine- and adefovir-associated HBV mutants.

106 after the virologic failure of rilpivirine-, lamivudine-, and emtricitabine-containing regimens.

107 The use of emtricitabine instead of lamivudine as part of cART was associated with better vi

108 -Saharan Africa have for many years included lamivudine as the sole hepatitis B virus (HBV) inhibitor

109 who had developed resistance to adefovir or lamivudine, as demonstrated by development of the rtA181

110 (HIV)/HBV-coinfected subjects maintained on lamivudine, as well as a prospective analysis of 76 lami

111 Entecavir demonstrated superior benefit to lamivudine at 48 weeks in nucleoside-naive patients with

112 ed with PEG-IFN (some were also treated with lamivudine) at 11 European and Asian hospitals; genotype

113 nd emtricitabine or combination abacavir and lamivudine background treatment.

114 Once generic coformulations of tenofovir/lamivudine become accessible, however, the appropriate p

115 s a polymerase that is not only resistant to lamivudine but also replicates nucleic acids to lower le

116 Telbivudine is more potent than lamivudine but is associated with a high rate of antivir

117 than in those given efavirenz with abacavir-lamivudine but not with tenofovir DF-emtricitabine.

118 sistant variants were partially inhibited by lamivudine, but remained fit in its presence.

119 In the lamivudine cohort, 11 (6.4%) of 171 cases of HBV recurre

120 o receive didanosine-stavudine or zidovudine-lamivudine, combined with efavirenz and/or nelfinavir.

121 of dual therapy with darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/rit

122 reatment with other HBV-active drugs such as lamivudine, compromises the efficacy of TDF due to possi

123 human immunodeficiency virus (HIV) receiving lamivudine-containing antiretroviral therapy (ART) witho

124 of HIV/HBV-coinfected patients on long-term lamivudine-containing ART had poor HIV and HBV suppressi

125 Although therapeutic responses to long-term lamivudine-containing HAART were comparable between HIV-

126 The median duration of lamivudine-containing highly active antiretroviral thera

127 Dual therapy with darunavir/ritonavir and lamivudine demonstrated noninferior therapeutic efficacy

128 ulation showed a >1,000-fold increase in the lamivudine EC(50).

129 are active against HBV infection, including lamivudine, emtricitabine, tenofovir, and, more recently

130 in 93% for efavirenz/nevirapine, in 81% for lamivudine/emtricitabine, in 59% for etravirine/rilpivir

131 in vivo study in chimeric mice harboring the lamivudine/entecavir triple mutant, FMCAP effectively re

132 uble (rtL180M/rtM204V) mutants as well as in lamivudine/entecavir triple mutants (L180M+S202G+M204V)

133 ine, as well as a prospective analysis of 76 lamivudine-experienced subjects who introduced tenofovir

134 hepatitis B (some nucleoside-naive and some lamivudine-experienced) were randomized 2:1 to receive T

135 enofovir exposure; most were also zidovudine/lamivudine exposed.

136 ors for resistance were age, viral load, and lamivudine exposure (P < .001).

137 r zidovudine for 6 weeks plus nelfinavir and lamivudine for 2 weeks (three-drug group).

138 214 (23%) patients treated with PEG-IFN +/- lamivudine for 52 weeks experienced flares.

139 sitive CHB patients treated with PEG-IFN +/- lamivudine for 52 weeks in a global randomized trial wer

140 uited if they were continuously treated with lamivudine for at least 10 years and maintained favorabl

141 Preventive therapy with lamivudine for patients who test positive for HBsAg and

142 ed nausea in the dolutegravir, abacavir, and lamivudine group (5% [n=17] vs 17% [n=55]; p<0.0001).

143 3 of 315) in the dolutegravir, abacavir, and lamivudine group (difference -0.6%, 95.002% CI -4.8 to 3

144 verse event was also shorter in the abacavir-lamivudine group (P<0.001).

145 There were 275 patients in the preventive lamivudine group and 475 control participants for the pr

146 None of the patients in the preventive lamivudine group developed HBV-related hepatic failure (

147 re was significantly shorter in the abacavir-lamivudine group than in the tenofovir DF-emtricitabine

148 More patients in the zidovudine-lamivudine group than in the tenofovir-emtricitabine gro

149 57 virologic failures (14%) in the abacavir-lamivudine group versus 26 (7%) in the tenofovir DF-emtr

150 ts vs. 27 of 394 patients) in the preventive lamivudine group.

151 Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effe

152 eron-alpha2a combined with lamivudine versus lamivudine improved HBeAg loss (1 RCT; 543 patients) and

153 Pegylated interferon-alpha2a versus lamivudine improved HBeAg seroconversion (1 RCT; 814 pat

154 02, 322 Chinese CHB patients were started on lamivudine in our center.

155 stance have been found with long-term use of lamivudine, in up to 76% of patients treated for 5 years

156 , abacavir, stavudine, didanosine (ddI), and lamivudine] individually or in combination [three HAART

157 tio of virological failure at week 240 using lamivudine instead of emtricitabine was 2.35 (95% CI, 1.

158 Lamivudine is increasingly being used to prevent hepatit

159 al therapy with lopinavir and ritonavir plus lamivudine is non-inferior to standard triple therapy.

160 A combination of adefovir and lamivudine is preferred to adefovir monotherapy for lami

161 leoside analog (3TC-TP, triphosphate form of lamivudine) is incorporated slowly, allowing the conform

162 Lamivudine (LAM) has been shown to prevent de novo hepat

163 sion to 40.3% at month 36 (P < 0.001), while lamivudine (LAM) or emtricitabine (FTC) use remained ste

164 hronic hepatitis B patients with preexisting lamivudine (LAM) resistance (LAM-R) undergoing liver tra

165 l data exist describing telbivudine (LdT) or lamivudine (LAM) use in late pregnancy for preventing he

166 e or in combination with interferon (IFN) or lamivudine (LAM) versus IFN or LAM were included.

167 riptase inhibitors approved for HBV therapy, lamivudine (LVD) and adefovir (ADV), in several ways: ET

168 02, or M250, which emerge in the presence of lamivudine (LVD) resistance substitutions M204I/V +/- L1

169 hibitor (K103N, V106M, Y181C, and G190A) and lamivudine (M184V) resistance mutations were quantified

170 Dolutegravir, in combination with abacavir-lamivudine, may provide a simplified regimen.

171 mended first-line therapies, and 30% were on lamivudine monotherapy.

172 e rate of antiviral resistance compared with lamivudine monotherapy.

173 The majority (73.8%) were exposed to lamivudine monotherapy.

174 ovudine (mother 300 mg; infants 2 mg/kg) and lamivudine (mothers 150 mg; infants 4 mg/kg) twice a day

175 cleoside reverse transcriptase inhibitor and lamivudine mutations present at >2% of the viral populat

176 = 128) or switch to darunavir/ritonavir and lamivudine (n = 129).

177 or coformulated dolutegravir, abacavir, and lamivudine (n=315), of whom 314 and 315 patients, respec

178 ts continuing in year 2 (entecavir, n = 243; lamivudine, n = 164) were assessed for serum hepatitis B

179 Genotyping and drug concentrations (lamivudine, nevirapine, and efavirenz) were measured on

180 in were associated with failure of stavudine-lamivudine-nevirapine (d4T/3TC/NVP; P < .01), and K103N,

181 hs in HIV-positive adults starting stavudine/lamivudine/nevirapine in Malawi, using Sanger, deep, clo

182 first-line regimen compared with zidovudine/lamivudine/NNRTI, PI resistance at switch (6.69; 2.49-17

183 lamivudine (PI group) or abacavir/zidovudine/lamivudine (NRTI group) in a clinical trial to prevent m

184 Treatment with lamivudine of patients infected with hepatitis B virus (

185 et regimen of dolutegravir plus abacavir and lamivudine once a day (dolutegravir group) or a three-ta

186 olutegravir at a dose of 50 mg plus abacavir-lamivudine once daily (DTG-ABC-3TC group) or combination

187 ing lamivudine prophylaxis versus initiating lamivudine only when clinically overt hepatitis occurred

188 i-HBV regimens were TDF/emtricitabine (57%), lamivudine or emtricitabine (19%), or TDF monotherapy (1

189 The inclusion of lamivudine or emtricitabine in cART did not influence th

190 zidovudine-lamivudine, the use of tenofovir-lamivudine or emtricitabine in combination with nevirapi

191 400 mg and ritonavir 100 mg twice daily and lamivudine or emtricitabine plus another nucleoside reve

192 Clinical trials of RPV administered with lamivudine or emtricitabine showed the emergence of E138

193 out baseline resistance (N = 4740) initiated lamivudine or emtricitabine with efavirenz/tenofovir or

194 apy with tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleoside rever

195 ine, stavudine, tenofovir, or abacavir, plus lamivudine or emtricitabine) with either efavirenz or ne

196 e combinations were studied (all paired with lamivudine or emtricitabine): efavirenz (EFV) plus zidov

197 GSS (gGSS), defined as the combined GSS for lamivudine or emtricitabine, abacavir, zidovudine, stavu

198 , combined with zidovudine or tenofovir plus lamivudine or emtricitabine.

199 e of them underwent pre-emptive therapy with lamivudine or other antiviral drugs and no one showed ep

200 Compared to control, lamivudine or telbivudine improved maternal HBV DNA supp

201 did not differ according to whether abacavir-lamivudine or tenofovir DF-emtricitabine was also given.

202 r antiviral activity when used with abacavir-lamivudine or tenofovir DF-emtricitabine.

203 given with with placebo-controlled abacavir-lamivudine or tenofovir disoproxil fumarate (DF)-emtrici

204 nitial therapy for HIV-1 infection: abacavir-lamivudine or tenofovir disoproxil fumarate (DF)-emtrici

205 se transcriptase inhibitors (NRTIs; abacavir/lamivudine or tenofovir disoproxil fumarate/emtricitabin

206 fumarate plus emtricitabine, zidovudine plus lamivudine, or abacavir plus lamivudine).

207 on period on oral cabotegravir plus abacavir-lamivudine, patients with viral suppression (plasma HIV-

208 gestation to lopinavir/ritonavir/zidovudine/lamivudine (PI group) or abacavir/zidovudine/lamivudine

209 avir (triple-nucleoside regimen), zidovudine/lamivudine plus EFV (3-drug EFV regimen) or zidovudine/l

210 trial of initial therapy with zidovudine and lamivudine plus either nevirapine or ritonavir-boosted l

211 lated LT between 1998 and 2010 and receiving lamivudine plus HBIg were followed for a median of 77 mo

212 y data, tenofovir-emtricitabine or tenofovir-lamivudine plus nevirapine is used in many resource-cons

213 comes than did treatment with zidovudine and lamivudine plus nevirapine.

214 regimens included stavudine/zidovudine plus lamivudine plus nevirapine/efavirenz.

215 viral treatment consisting of zidovudine and lamivudine plus ritonavir-boosted lopinavir resulted in

216 ibitors (tenofovir/emtricitabine or abacavir/lamivudine) plus a nonnucleoside reverse transcriptase i

217 vide pharmacoeconomic support for the use of lamivudine prophylaxis in patients undergoing chemothera

218 Our results indicate that the use of lamivudine prophylaxis is cost-effective.

219 are the costs and clinical outcomes of using lamivudine prophylaxis versus initiating lamivudine only

220 ncremental cost-effectiveness ratio of using lamivudine prophylaxis was $33,514 per life year saved.

221 Even though the use of lamivudine prophylaxis was associated with an incrementa

222 cer deaths were also reduced from 47-39 with lamivudine prophylaxis, presumably because of the increa

223 with hepatitis B immunoglobulin (HBIg) plus lamivudine reduces the risk of hepatitis B virus (HBV) r

224 ine is preferred to adefovir monotherapy for lamivudine-refractory hepatitis B patients.

225 tis B patients but it is not as effective in lamivudine-refractory patients.

226 al therapy with lopinavir and ritonavir plus lamivudine regimen warrants further clinical research an

227 61.5% vs 25.0%, P = .03), and development of lamivudine resistance (31.3% vs 12.2%; P < .0001).

228 o of these substitutions are associated with lamivudine resistance (LVDr) in the tyrosine-methionine-

229 he emergence of HBV DNA mutations conferring lamivudine resistance (rtM204I/V) were determined.

230 to many sites of HBV proteins confirms that lamivudine resistance is a complex trait encoded by the

231 with levels of HBV DNA >/=3 log10 IU/mL and lamivudine resistance mutations (HBV polymerase or rever

232 rbations of hepatitis, HBeAg seroconversion, lamivudine resistance, and liver disease-related death t

233 aa changes, other than those associated with lamivudine resistance, were observed in patients with pe

234 variant, indicating the convergent nature of lamivudine resistance.

235 re observed, 5 of which were associated with lamivudine resistance.

236 from 5 NRTI-treated patients, including the lamivudine-resistance mutation V173L (in 5 samples), the

237 For lamivudine resistant hepatitis B virus infection, adefov

238 activity against both adefovir-resistant and lamivudine-resistant double (rtL180M/rtM204V) mutants as

239 oside analogs, the more rapid development of lamivudine-resistant HBV in patients who are HIV-positiv

240 to the wild-type baseline isolate, while the lamivudine-resistant HBV quasispecies population showed

241 sistance profile and is fully active against lamivudine-resistant HBV.

242 nd entecavir have decreased efficacy against lamivudine-resistant HBV.

243 r dipivoxil is a promising new treatment for lamivudine-resistant hepatitis B mutants.

244 disoproxil fumarate (TDF) is active against lamivudine-resistant hepatitis B virus (HBV) infection,

245 ir were shown to be effective in suppressing lamivudine-resistant hepatitis B.

246 Lamivudine-resistant mutants appear in more than 50% of

247 therapies on the same genome; 31 clones had lamivudine-resistant mutants only.

248 o an accumulation of HIV-1 variants with the lamivudine-resistant mutation, M184V.

249 osine analogue 35 was cross-resistant to the lamivudine-resistant variants (HIV-1M184V).

250 and effective for treatment of patients with lamivudine-resistant, chronic HBV infection.

251 girls (but not boys) exposed in utero to ZDV/lamivudine/ritonavir-boosted lopinavir (LPV/r) had a hig

252 nevirapine or abacavir with zidovudine plus lamivudine, routine viral load monitoring was not perfor

253 The NRTIs were lamivudine + stavudine, zidovudine, or tenofovir.

254 Exposure to lamivudine and to lamivudine-stavudine were also associated with an increa

255 erivatives, key intermediates for asymmetric lamivudine synthesis, was elucidated.

256 (ART) with either tenofovir-emtricitabine or lamivudine (tenofovir group) or zidovudine-lamivudine (z

257 ed with high-level resistance to zidovudine, lamivudine, tenofovir, or abacavir.

258 er in patients randomly assigned to abacavir-lamivudine than in those assigned to tenofovir DF-emtric

259 ceive coformulated abacavir, zidovudine, and lamivudine (the nucleoside reverse-transcriptase inhibit

260 llimeter received nevirapine plus zidovudine-lamivudine (the observational group).

261 roup) or lopinavir-ritonavir plus zidovudine-lamivudine (the protease-inhibitor group) from 26 to 34

262 With preventive lamivudine, the relative risk for both HBV reactivation

263 Compared with zidovudine-lamivudine, the use of tenofovir-lamivudine or emtricita

264 However, HBIg is expensive, and lamivudine therapy is limited by drug resistance.

265 r 18 years of age (hazard ratio = 2.46), and lamivudine therapy prior to HBeAg seroconversion (hazard

266 Lamivudine therapy selects for the M184V mutation.

267 achieve protective HBV immunity or lifelong lamivudine therapy should prevent posttransplant HBV inf

268 virus infection, adefovir should be added to lamivudine to reduce the risk of adefovir-resistant muta

269 ed in 31% of entecavir-treated versus 25% of lamivudine-treated patients (P = NS).

270 Higher proportions of entecavir-treated than lamivudine-treated patients achieved cumulative confirme

271 Similar proportions of entecavir-treated and lamivudine-treated patients achieved HBeAg seroconversio

272 ar 2, 74% of entecavir-treated versus 37% of lamivudine-treated patients achieved HBV DNA <300 copies

273 , and 79% of entecavir-treated versus 68% of lamivudine-treated patients normalized ALT levels.

274 eAg-negative hepatitis increased to 2.64% in lamivudine-treated subjects but did not increase in thos

275 status (47% HBeAg-positive), and duration of lamivudine treatment (mean, 3.8 years).

276 The role of specific genotypes and prior lamivudine treatment in the delayed response to TDF warr

277 We evaluated continued entecavir and lamivudine treatment through 96 weeks.

278 After a median of 45 months of lamivudine treatment, HIV-1 RNA and HBV DNA were detecta

279 ies that reported the efficacy of preventive lamivudine versus control on HBV reactivation in patient

280 Pegylated interferon-alpha2a combined with lamivudine versus lamivudine improved HBeAg loss (1 RCT;

281 troviral Design Encompassing Lopinavir/r and Lamivudine vs LPV/r based standard therapy) is a 48 week

282 The use of lamivudine was associated with more virological failure

283 In contrast, removal of acyclovir and lamivudine was mainly attributable to slower microbial p

284 Lamivudine was the first approved agent, but its use lea

285 Lamivudine was well tolerated, and no adverse effects we

286 riptase inhibitors, especially stavudine and lamivudine, was associated with possible mitochondrial d

287 Efavirenz (600 mg/d) and stavudine plus lamivudine were administered in addition to standard ant

288 of lamivudine and for settings where generic lamivudine will be available.

289 EFV plus tenofovir/emtricitabine or abacavir/lamivudine with NAFLD were randomized 1:1 to switch from

290 scriptase inhibitors (2NRTI, mainly abacavir+lamivudine) with a non-nucleoside reverse transcriptase

291 therapy (lopinavir/ritonavir, stavudine, and lamivudine) with plasma HIV RNA <50 copies per ml by wee

292 to coformulated dolutegravir, abacavir, and lamivudine, with no treatment-emergent resistance.

293 drugs, including efavirenz, nevirapine, and lamivudine, with nucleoside resistance including type 2

294 r lamivudine (tenofovir group) or zidovudine-lamivudine (zidovudine group).

295 Lamivudine, zidovudine, emtricitabine, and tenofovir had

296 l antiretroviral therapy with efavirenz plus lamivudine-zidovudine (EFV+3TC-ZDV), atazanavir plus did

297 mized to 3 antiretroviral treatment arms: A (lamivudine-zidovudine plus efavirenz, n = 289), B (ataza

298 After 14 days of monotherapy, lamivudine/zidovudine was added to the VCV arms; subject

299 labor and were randomly assigned to receive lamivudine/zidovudine, emtricitabine/tenofovir, or lopin

300 ving placebo were treated with efavirenz and lamivudine/zidovudine; the planned treatment duration wa